Image via GNW — Germany
Last updated
Boehringer Ingelheim: Ma Activity
Boehringer Ingelheim acquired Evax AG, a Swiss biotech company specializing in equine health, expanding its animal health portfolio.
Source: GNW — Germany
The leadership read
Consolidation shifts the leadership question from growth to integration. For Boehringer Ingelheim in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across EMEA, watch whether the integration is properly resourced; deals are won or lost the year after they close.
Market context: This lands while the Talent Market Index reads 102.2 (Warm) — down 1.7 versus the prior month — and EMEA signal share is steady (0pts).
Boehringer Ingelheim: 5 signals in the last 90 days — above the Biotech & Pharma median of 1 across 25 tracked companies; 0.1% of MitchelLake's Americas signal flow; 5 tracked across 68 days.
MitchelLake in this thematic
Also at Boehringer Ingelheim →
More signals across Biotech & Pharma
Ma Activity · EMEA
Biogen →Biogen completed acquisition of Apellis Pharmaceuticals, a leader in complement-driven disease treatments
Ma Activity · EMEA
Gilead Sciences →Gilead Sciences acquired Tubulis, a Germany-based clinical-stage biotechnology company for up to USD 5.0 billion
Partnership · EMEA
Flagship Pioneering →Flagship Pioneering announced a strategic collaboration with a Lean Business Services Company to advance healthcare innovation and AI-enabled biomedical research in Saudi Arabia, leveraging national health data capabilities and precision medicine expertise to support Vision 2030.
Product Launch · EMEA
Bristol Myers Squibb →Bristol Myers Squibb reported positive Phase III clinical trial results for mezigdomide (multiple myeloma) and early-stage CAR T-cell therapy arlocabtagene autoleucel with strong response rates and manageable safety profiles, presented at European Hematology Association Congress 2026.
Product Launch · EMEA
Amgen →European Commission approved Amgen's IMDYLLTRA® for extensive-stage small cell lung cancer treatment, demonstrating 40% reduction in death risk versus chemotherapy in Phase 3 trial
Partnership · EMEA
UCB →UCB expanded its existing alliance with Cancer Research UK, adding two new UCB-nominated projects to advance novel cancer therapies
Intelligence powered by Autonodal ↗
Nearby in the record